Rollprint adds director of technical services

New position created to add r&d capacity and support customers

Rollprint Packaging Products, the US supplier of packaging materials for the healthcare and food industries, has welcomed Dr Henk Blom as director of technical services. He reports to Doug Dodrill, vice president of technology.

‘As the demand for Rollprint products continues to grow, it was important to support our customers with additional r&d capability so we created the new position,’ Dodrill said.

Having spent the past 12 years at Baxter Healthcare Corporation, Blom brings significant medical device technical expertise to the position.

‘Henk’s background enables him to look at the big picture – materials, distribution, processing, failure analysis, etc. – to help our customers find ideal packaging solutions for their specific product requirements,’ added Dodrill.

You may also like

Packaging

Easy-to-open Barex replacement takes on single-dose applications

Peelable Exponent is designed for hard-to-hold and sensitive chemicals
Packaging

Rollprint introduces Exponent clear flexible film for high-barrier pharmaceutical applications

The result of a collaboration between Rollprint and Ineos
Packaging

Rollprint Ghost technology thwarts counterfeiters

The process creates a repeating watermark embedded in flexible packaging materials
Packaging

Colour-changing sealant enhances pack security

Allows a film of one colour to transfer a peel indicator of a different colour
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development

Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies

Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Subscribe now